Walkty, Andrew - University of Manitoba - Department of Medical Microbiology and Infectious Diseases

个人简介

Assistant Professor, Departments of Medical Microbiology and Internal Medicine, University of Manitoba Degrees: BSc Pharm ( Manitoba , 1999), M.D. ( Manitoba , 2003), FRCPC Internal Medicine ( Manitoba , 2007), FRCPC Infectious Diseases ( Manitoba , 2008), FRCPC Medical Microbiology ( Manitoba , 2009)

研究领域

Antimicrobial resistance, including antimicrobial susceptibility and mechanisms of resistance

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Walkty A, Van Caeseele P, Hilderman T, Buchan S, Weiss E, Sloane M, Fatoye B. Mumps in prison: description of an outbreak in Manitoba, Canada. Can J Public Health 2011;102:241-4. Walkty A, Abbott B, Swirsky N, Safneck J. Keeping an open mind about meningitis: a case report of carcinomatous meningitis. CJEM 2011;13:352-6. Hatakka A, Klein J, He R, Piper J, Tam E, Walkty A. Acute hepatitis as a manifestation of parvovirus B19 infection. J Clin Microbiol 2011;49:3422-4. Karlowsky JA, Lagace-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD. Antimicrob Agents Chemother 2011;55:3169-75. Walkty A, DeCorby M, Lagace-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 Study). Antimicrob Agents Chemother 2011;55:2992-4. Lagace-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2011;55:2434-7. Walkty A, Adam HJ, Laverdiere M, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA). In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011;69:348-55.